Ajanta Pharmaceuticals Ltd.

“Ajanta Pharma is a well-run, high-ROIC specialty branded-generics franchise with a genuine but narrow moat across India and African emerging markets, disciplined owner-operator management, and a strengthening earnings trajectory — but at 37x trailing P/E the price already fully reflects this quality, leaving expected 10-year returns in the 2.5–3x range rather than the 4–5x needed to justify a buy over alternatives; the right action is to track for a 20–25% pullback to the ₹2,350–2,500 range where the risk/reward becomes compelling.”